Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy

Kirova, Youlia; Stoppa‐Lyonnet, Dominique; Savignoni, Alexia; Sigal‐Zafrani, Brigitte; Fabre, Nicolas; Fourquet, A.

doi:10.1016/j.ejca.2005.02.037

Cited by 121 publications

(84 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown in the studies by Scheuer et al 38 and Meijers-Heijboer et al, 39 prophylactic SO has been demonstrated to offer about a 50% reduction of the risk of either a first BC in women with no previous BC or contralateral BC in women with a previous BC. 10,11,[20][21][22] In the present series, 7 BCs occurred after SO: 3 BCs among the 16 women with no personal history of BC, and 4 contralateral BCs among patients with a history of BC. Due to the limited sample size and short follow-up of our series, mainly composed of patients with previous BC, no conclusions can be drawn concerning the effect of SO on BC in these patients.…”

Section: Discussionsupporting

confidence: 41%

“…9 The 10-year risk of contralateral BC is more than 5-fold higher than that observed after sporadic cancer (37% compared with 7%). 10,11 However, the risk of ipsilateral disease, at least during the first 10 years after treatment of a first BC, does not appear to be increased. 11,12 According to this same study, the cumulative risk of ovarian cancer at 70 years of age was 39% (95% CI: 18-54) and 11% (95% CI: 2.4-19) for BRCA1 and BRCA2 mutation carriers, respectively, whereas the risk in the age-matched general population is about 1%.…”

mentioning

confidence: 99%

“…10,11 However, the risk of ipsilateral disease, at least during the first 10 years after treatment of a first BC, does not appear to be increased. 11,12 According to this same study, the cumulative risk of ovarian cancer at 70 years of age was 39% (95% CI: 18-54) and 11% (95% CI: 2.4-19) for BRCA1 and BRCA2 mutation carriers, respectively, whereas the risk in the age-matched general population is about 1%. 9 However, the risks of both breast and ovarian cancers have been reported to be slightly modified by the site of the gene mutation and by either genetic or nongenetic modifying factors.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND.Prophylactic salpingo‐oophorectomy (SO), which is recommended in BRCA1/2 mutation carriers, still needs to be reappraised.METHODS.In all, 89 BRCA1/BRCA2 mutation carriers underwent SO between 1994–2004. Past medical and familial history, SO, results and survival after SO were analyzed.RESULTS.The series consisted of 56 BRCA1 and 33 BRCA2 mutation carriers. All but 1 had a family history of breast (BC) and/or ovarian cancer; 42 BRCA1 and 31 BRCA2 had a personal history of BC. The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) years (P = .03) for women with previous BC. Occult ovarian (n = 2) and/or fallopian (n = 3) carcinomas were found in 4 patients (4.5%): 1 experienced recurrence (4 years), 2 are disease‐free (26 and 38 months of follow‐up), and 1 died from BC (12 months). Among the other 69 patients with previous BC (median follow‐up, 42 months), 14 developed ipsilateral or contralateral BC and 8 developed metastatic disease. Among the 16 patients without previous BC (median follow‐up, 27 months), 3 developed BC. Of the 89 patients, 85 are still alive: 3 died from BC and 1 died from pancreatic cancer. No peritoneal malignancy was observed.CONCLUSIONS.This study shows that prophylactic SO remains an important option for BRCA1/2 mutation carriers as asymptomatic ovarian/fallopian cancers were found in 4.5% of patients. However, a longer follow‐up and larger series are required to more precisely evaluate the benefits of this procedure in terms of BC incidence, peritoneal malignancy, or recurrence. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 41%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Women with one or more FDR showed an increased incidence of MBBC compared to none, which is comparable with the results found in the literature [14][15][16][17]23,25].…”

Section: Discussionsupporting

confidence: 90%

“…These women are often advised not to have a BCT, but an ablation. Kirova et al in their study on BCT in BRCA1/2 mutation carriers showed no difference in local control between mutation carriers, non-carriers with FH and controls [25,27]. They also mentioned that mutation carriers might be more sensitive to radiotherapy.…”

Section: Discussionmentioning

confidence: 94%

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

et al. 2015

View full text Add to dashboard Cite

Background. The aim of this study is to analyze the impact of first degree relative (FDR) of young breast cancer patients. Methods. Data were used from our prospective population-based cohort study which started in 1983. The family history (FH) was registered with regard to FDR: the presence or absence of invasive breast cancer in none vs. one or more FDRs at any age. Results. A total of 1109 women, 50 years with 1128 breast conserving treatments was seen. The incidence of FDR was 17.0% for one FDR and 3.2% 2 FDR. The three groups, none, 1 or 2 FDR, were comparable. The local failure rate is comparable for all three groups. Women with a positive FH and metachronous bilateral breast cancer (MBBC) showed a lower local failure (HR 0.2; 95% CI 0.05-0.8). A positive FH was an independent predictor for a better disease-specific survival (HR 0.6; 95% CI 0.4-0.9). Conclusion. A positive FH, based on FDR implies a better prognosis in relation to survival for young women treated with BCT. In contrast to no FH for FDR, MBBC in women with a positive FH was not associated with an increased risk of local recurrence.

show abstract

Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer

Wan

Ouyang

et al. 2021

JAMA Netw Open

View full text Add to dashboard Cite

IMPORTANCE Whether patients with breast cancer who carry a BRCA1/2 variant can safely undergo breast-conserving therapy (BCT) remains controversial. OBJECTIVE To compare survival rates after BCT vs mastectomy in BRCA1/2 variant carriers and noncarriers in a large series of unselected patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS In this cohort study, a large consecutive series of 8396 unselected patients with primary breast cancer underwent either BCT, mastectomy with radiotherapy, or mastectomy alone from October 1, 2003, to May 31, 2015, at the Breast Center of Peking University Cancer Hospital in China. All patients were assessed for BRCA1/2 germline variant status. Statistical analysis was performed from May 1 to September 30, 2020. MAIN OUTCOMES AND MEASURESThe primary outcomes were breast cancer-specific survival (BCSS) and overall survival (OS); secondary outcomes included recurrence-free survival, distant recurrence-free survival, and ipsilateral breast tumor recurrence. RESULTSOf these 8396 Chinese patients (8378 women [99.8% women]; mean [SD] age, 50.8 [11.4] years; 187 BRCA1 carriers, 304 BRCA2 carriers, and 7905 noncarriers), 3135 (37.3%) received BCT, 1511 (18.0%) received mastectomy with radiotherapy, and 3750 (44.7%) received mastectomy alone. After a median follow-up of 7.5 years (range, 0.3-16.6 years), both BRCA1 and BRCA2 variant carriers treated with BCT had similar rates of survival compared with those treated with mastectomy with radiotherapy (BCSS: hazard ratio [HR] for BRCA1, 0.58 [95% CI, 0.16-2.10]; P = .41; HR for

show abstract

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy

Cited by 121 publications

References 44 publications

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer

Contact Info

Product

Resources

About